For the Inventor, By the Inventor

Enter assignee name

Vascular Biogenics Ltd.

USPTO Granted Patents = 46

CIPO Patents = 45

EPO Patents = 28

Trademarks = 4

Forward Citations = 446

Loading Chart...

Loading Chart...

48 inventors (with patents filed for the assignee):

Eyal Breitbart (26 out of 29 patents)

Dror Harats (24 out of 31 patents)

Gideon Halperin (19 out of 20 patents)

4. Eti Kovalevski-Ishai (16 out of 17 patents)

5. Niva Yacov (13 out of 14 patents)

6. Jacob George (11 out of 16 patents)

7. Itzhak Mendel (10 out of 12 patents)

8. Erez Feige (8 out of 9 patents)

9. Shoshana Greenberger (8 out of 11 patents)

10. Livnat Bangio (7 out of 7 patents)

11. Naamit Sher (5 out of 5 patents)

12. Andrea Leubitz (4 out of 5 patents)

13. Yaniv Salem (4 out of 6 patents)

14. Nira Bloom (4 out of 4 patents)

15. Michael R Peled (4 out of 25 patents)

Core Competencies:

Oxidized Lipids

Anti-Angiogenic Agents

Glioblastoma Treatment

Endothelial Cell-Specific Promoters

Phospholipid Formulations

Atherosclerosis Prevention

Polynucleotide Constructs

Fibrosis Treatment

FAS-Chimera Adenovirus Vector

Cancer Therapy

Inflammatory Diseases

Targeted Downregulation

46 patents: Sort by Forward Citations

1. 11697682 - Motile sperm domain containing protein 2 antibodies and methods of use thereof (2023-07-11),

2. 11191848 - Methods of inducing responsiveness to anti-angiogenic agent (2021-12-07),

3. 10464957 - Oxidized lipids and methods of use thereof (2019-11-05),

4. 10383954 - Methods of inducing responsiveness to anti-angiogenic agent (2019-08-20),

5. 10369196 - Compositions and methods for treating glioblastoma GBM (2019-08-06),

6. 10206936 - Oxidized lipids and treatment or prevention of fibrosis (2019-02-19),

7. 10022388 - Oxidized lipids and treatment or prevention of fibrosis (2018-07-17),

8. 9968622 - High-purity phospholipids (2018-05-15),

9. 9771385 - Oxidized lipids (2017-09-26),

10. 9682154 - Methods of inducing responsiveness to anti-angiogenic agent (2017-06-20),

11. 9567605 - Methods for use of a specific anti-angiogenic adenoviral agent (2017-02-14),

12. 9403887 - Endothelial cell-specific polynucleotides and use thereof (2016-08-02),

13. 9254297 - Formulations and dosage forms of oxidized phospholipids (2016-02-09),

14. 9206206 - Oxidized lipid compounds and uses thereof (2015-12-08),

15. 9200056 - FAS-chimera adenovirus vector (2015-12-01),

Vascular Biogenics Ltd. (VBL) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class treatments for cancer and immune-inflammatory diseases. VBL's approach is based on the area of gene therapy and utilizes its proprietary viral platform technology to deliver targeted therapies directly to the site of disease. The company's lead product candidate, VB-111, is being evaluated in multiple clinical trials for various cancer indications.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

46 Patents

#1 in Modiin

#104 in Israel

#14,674 in the World

Vascular Biogenics Ltd.

Forward Citations = 446

48 inventors:

Eyal Breitbart (26 out of 29 patents)

Dror Harats (24 out of 31 patents)

Gideon Halperin (19 out of 20 patents)

4. Eti Kovalevski-Ishai (16 out of 17 patents)

5. Niva Yacov (13 out of 14 patents)

Please report any incorrect information to support@idiyas.com

Loading…